Clinical trials
Cell Therapy clinical trials
Below are recruiting cell therapy clinical trials, each written for real people, not researchers. We’re tracking 1,109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04857164RecruitingPhase 2
Pembrolizumab plus chemotherapy for recurrent or metastatic throat cancer
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04992559RecruitingPhase 2
Toripalimab after surgery and chemoradiation for head and neck cancer
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
Guangzhou, GuangdongAges 18–70 - NCT04999943RecruitingPhase 1
Testing two blood-cancer medicines plus eDC in older MDS patients
This early-phase study tests a combination of two standard medicines for myelodysplastic syndrome (MDS) along with an added eDC therapy in people age 60 and older. It may help improve blood counts or disease control for those who cannot or do not want stem cell transplant.
BeijingAges 60 years+ - NCT06081673RecruitingPhase 2
Penpulimab plus chemo before and after surgery for head and neck cancer
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07120698RecruitingPhase 2
MRD-guided sintilimab after surgery for NSCLC
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
Guangzhou, GuangdongAges 28–75 - NCT07180927RecruitingPhase 1/Phase 2
DLL3 car-t therapy for recurrent brain tumors
This trial tests a new immune therapy called DLL3 CAR-T cells for people with brain tumors that have come back or not responded to treatment. It aims to see if these specially designed cells can attack the tumor safely.
Shenzhen, GuangdongAges 2–70 - NCT07304232RecruitingPhase 2
Chidamide after stem cell transplant for AML
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
Shijiazhuang, HebeiAges 18–75 - NCT07410975RecruitingPhase 2
Immunotherapy and chemo before surgery for lung cancer
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06326008RecruitingPhase 1
Donor immune cell therapy for leukemia that returned after treatment
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
Beijing, Beijing MunicipalityAges 1–18 - NCT06974786RecruitingPhase 2
T-cell engager vs stem cell transplant for newly diagnosed myeloma
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
Birmingham, AlabamaAges 19 years+ - NCT06646497RecruitingPhase 2
Stem cell transplant for tough aplastic anemia in adults 40-60
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
Paris, FranceAges 40–60 - NCT07475182RecruitingEarly Phase 1
Cell therapy for advanced solid tumors with specific proteins
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
Haikou, HainanAges 18–75 - NCT05011045Recruiting
Brain radiation study tracking thinking and memory changes
This study looks at how whole-brain radiation affects thinking, memory, and other brain function in people with blood cancers that involve the brain. It may help doctors understand what to expect and which supportive treatments or monitoring could be useful.
Houston, TexasAges 18 years+ - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Tucson, ArizonaAges 18 years+ - NCT06564324RecruitingPhase 3
Comparing taletrectinib to standard therapy for ROS1-positive lung cancer
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
Hefei, AnhuiAges 18 years+ - NCT07150663RecruitingPhase 3
Megestrol acetate with chemoradiation for stage III lung cancer
This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.
Wuhan, HubeiAges 18–85 - NCT06116110Recruiting
Long-term follow-up after gene therapy treatment
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Gilbert, ArizonaAges 18 years+ - NCT06279104Recruiting
Comparing treatments for ovarian clear cell carcinoma
This study compares different ways to treat ovarian clear cell carcinoma, a rare type of ovarian cancer. It is for women whose cancer has come back or not gone away after platinum chemotherapy, or those newly diagnosed.
Wuhan, HubeiAges 18–75 - NCT05244239RecruitingPhase 1
Radiation plus lurbinectedin for advanced small cell lung cancer
This trial studies whether adding palliative (comfort-focused) radiation to the medicine lurbinectedin can better control extensive-stage small cell lung cancer. It may help reduce problems from tumors in places like bones and organs.
Atlanta, GeorgiaAges 18 years+ - NCT05679895RecruitingPhase 1
Study drug OC-1 for CD1a-positive T-ALL or T-LL after relapse
This Phase 1 trial tests the safety and early signs of benefit of OC-1 in people with relapsed or hard-to-treat T-cell leukemia/lymphoma (T-ALL/LL) that has a CD1a marker. You may be considered if standard treatments didn’t work or the cancer returned, and if your organs and infections are controlled.
BarcelonaAges 2 years+ - NCT06208826RecruitingPhase 2
Immunotherapy maintenance after surgery for head and neck cancer
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT06712355RecruitingPhase 3
Testing an experimental drug with chemo for newly diagnosed extensive-stage small cell lung cancer
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
Tucson, ArizonaAges 18 years+ - NCT07642024RecruitingPhase 2/Phase 3
BL-B01D1 Plus Osimertinib Before Surgery for EGFR-Mutated Lung Cancer
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cell therapy?
- Yes. Clin2 currently lists 1,109 recruiting cell therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cell therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cell therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.